Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...
Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...